2003-09-08-世界卫生组织-INN_Recommended_List_50_20页_237kb

报告摘要

Summary of International Nonproprietary Names for Pharmaceutical Substances (INN)

Core Content

The document provides a list of Recommended International Nonproprietary Names (INN) for pharmaceutical substances, specifically List 50, as well as Proposed INN (Prop. INN) from List 88 and Amendments to previous lists. These names are selected by the World Health Organization (WHO) to ensure standardized naming for pharmaceutical substances across different languages and countries. The INN system is designed to promote clarity and consistency in the naming of drugs, which is essential for global communication in the pharmaceutical field.

Main Points

INN Definition: International Nonproprietary Names (INN) are non-proprietary names assigned by the WHO for pharmaceutical substances. These names are used to identify substances without implying any endorsement of their medicinal use.
List 50: This list contains 50 recommended INN names, which are the result of a formal selection process. Each name includes the Latin, English, French, and Spanish versions, along with the chemical name, molecular formula, and graphic formula where applicable.
List 88: This list contains proposed INN names. It includes updates and changes to the previously recommended names, such as the replacement of the chemical name for lurasidone and the molecular formula for axomadol.
Amendments: Some names in previous lists have been updated. For instance, the name lurasidonum was replaced with lurasidone, and the molecular formula for axomadol was corrected to C₁₆H₂₅NO₃.
Language Coverage: The INN system is multilingual, with names provided in Latin, English, French, and Spanish to ensure global accessibility.
Cumulative Lists: The Cumulative List No. 10, 2002 is referenced as the source of both proposed and recommended INN names. It is available only in CD-ROM format.
Procedure and Principles: The procedures and guiding principles for selecting INN are outlined and will only be published in the odd-numbered proposed INN lists. These principles ensure that names are chosen based on scientific accuracy, clarity, and the need for international standardization.

Key Information

Purpose of INN: To provide a standardized, non-proprietary name for pharmaceutical substances to facilitate global communication and usage in medicine and pharmacy.
Inclusion in INN Lists: The inclusion of a name in the list does not imply any recommendation for its use in medicine or pharmacy.
Language Variations: The document includes names in Latin, English, French, and Spanish, ensuring that the names are accessible to a wide range of users.
Molecular Formula and Structure: For many substances, the document includes the molecular formula and a graphic formula, which are important for chemical identification.
Updates and Corrections: The document highlights that some names and formulas have been updated in later lists, such as the correction of the molecular formula for axomadol and the name for lurasidone.
Format: The INN list is structured with a table that includes multiple language versions, chemical names, molecular formulas, and graphic formulas. Some entries contain complex chemical structures, which are represented in both text and formula form.

Summary Table of Selected INN

Substance	INN (Latin/English/French/Spanish)	Chemical Name	Molecular Formula
acidum arundicum	arundic acid	(2R)-2-propyloctanoic acid	C₁₁H₂₂O₂
acidum salcaprozicum	salcaprozic acid	8-(2-hydroxybenzamido)octanoic acid	C₁₅H₂₁NO₄
alvocidibum	alvocidib	(-)-2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methyl-4-piperidyl]-4H-chromen-4-one	-
anatibantum	anatibant	(2S)-N-[3-(4-carbamimidoylbenzamido)propyl]-1-{2,4-dichloro-3-[[2,4-dimethyl-8-quinolyloxy]methyl]phenylsulfonyl}pyrrolidine-2-carboxamide	-
ataciguatum	ataciguat	5-chloro-2-[(5-chloro-2-thienyl)sulfonylamino]-N-[4-(morpholin-4-ylsulfonyl)phenyl]benzamide	C₂₁H₁₉Cl₂N₃O₆S₃
atazanavirum	atazanavir	dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate	C₃₈H₅₂N₆O₇
etravirinum	etravirine	4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy]-3,5-dimethylbenzonitrile	C₂₀H₁₅BrN₆O
gemcabenum	gemcabene	2,2,2',2'-tetramethyl-6,6'-oxydihexanoic acid	C₁₆H₃₀O₅
lurasidonum	lurasidone	(3aR,4S,7R,7aS)-2-{[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione	C₂₈H₃₆N₄O₂S
matuzumabum	matuzumab	immunoglobulin G1, anti-(human epidermal growth factor receptor) (humanized MAb 425 γ1 chain), disulfide with humanized MAb 425 κ-chain, dimer	C₁₀H₁₄N₂O₅
meclinertantum	meclinertant	2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]tricyclo[3.3.1.1³,⁷]decane-2-carboxylic acid	C₃₂H₃₁ClN₄O₅
oxeglitzarum	oxeglitzar	(2E,4E)-5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid	C₁₉H₂₂O₄
rupintrivirum	rupintrivir	ethyl (2E,4S)-4-{[(2R,5S)-2-(4-fluorobenzyl)-6-methyl-5-(5-methyl-1,2-oxazol-3-carboxamido)-4-oxoheptanamido]-5-{[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate	C₃₁H₃₉FN₄O₇
sorafenib	sorafenib	4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N₂-methylpyridine-2-carboxamide	C₂₁H₁₆ClF₃N₄O₃
squalaminum	squalamine	(24R)-3β-[3-(4-aminobutylamino)propylamino]-7α-hydroxy-5α-cholestan-24-yl hydrogen sulfate	C₃₄H₆₅N₃O₅S
tacedinalinum	tacedinaline	4-acetamido-N-(2-aminophenyl)benzamide	C₁₅H₁₅N₃O₂
tolevamerum	tolevamer	poly[1-(4-sulfophenyl)ethylene]	(C₈H₈O₃S)ₙ
etiprednol dicloacetate	etiprednol dicloacetate	ethyl 17α-(dichloroacetoxy)-11β-hydroxy-3-oxoandrosta-1,4-diene-17β-carboxylate	C₂₄H₃₀Cl₂O₆
barixibatum	barixibat	11-(D-glucanamido)-N-{2-[(1S,2R,3S)-3-hydroxy-3-phenyl-2-(2-pyridyl)-1-(2-pyridylamino)propyl]phenyl}undecanamide	C₄₂H₅₅N₅O₈
disufentonum natricum	disufenton de sodio	disodium 4-(tert-butyliminomethyl)benzene-1,3-disulfonate N-oxide	C₁₁H₁₃NNa₂O₇S₂
dofequidarum	dofequidar	1-(diphenylacetyl)-4-[(2RS)-2-hydroxy-3-(5-quinolyoxy)propyl]piperazine	C₃₀H₃₁N₃O₃
posizolidum	posizolid	(5R)-3-(4-{1-[((2S)-2,3-dihydroxypropanoyl)-1,2,3,6-tetrahydro-4-pyridyl]-3,5-difluorophenyl)-5-[(isoxazol-3-yloxy)methyl]oxazolidin-2-one	-
telbivudinum	telbivudine	1-(2-deoxy-β-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione	C₁₀H₁₄N₂O₅
bortezomibum	bortézomib	[(1R)-3-méthyl-1-[[(2S)-3-phenyl-2-[(pyrazinylcarbonyl)amino]= propanoyl]amino]butyl}boronique	C₁₉H₂₅BN₄O₄
cinacalcetum	cinacalcet	N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine	C₂₂H₂₂F₃N
darunavirum	darunavir	(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-[(1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl]carbamate	C₃₀H₃₁FN₄O₇
etravirinum	etravirine	4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy]-3,5-dimethylbenzonitrile	C₂₀H₁₅BrN₆O
gemcabenum	gemcabene	2,2,2',2'-tetramethyl-6,6'-oxydihexanoic acid	C₁₆H₃₀O₅
latidectinum	latidectine	1-[4-[(methoxyacetyl)amino]phenyl]cyclopentanecarboxylate	C₂₈H₃₆N₄O₂S
matuzumabum	matuzumab	immunoglobulin G1, anti-(human epidermal growth factor receptor) (humanized MAb 425 γ1 chain), disulfide with humanized MAb 425 κ-chain, dimer	C₁₀H₁₄N₂O₅
meclinertantum	meclinertant	2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]tricyclo[3.3.1.1³,⁷]decane-2-carboxylic acid	C₃₂H₃₁ClN₄O₅
rupintrivirum	rupintrivir	ethyl (2E,4S)-4-{[(2R,5S)-2-(4-fluorobenzyl)-6-methyl-5-(5-methyl-1,2-oxazol-3-carboxamido)-4-oxoheptanamido]-5-{[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate	C₃₁H₃₉FN₄O₇
sorafenib	sorafenib	4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N₂-methylpyridine-2-carboxamide	C₂₁H₁₆ClF₃N₄O₃
squalaminum	squalamine	(24R)-3β-[3-(4-aminobutylamino)propylamino]-7α-hydroxy-5α-cholestan-24-yl hydrogen sulfate	C₃₄H₆₅N₃O₅S
tacedinalinum	tacedinaline	4-acetamido-N-(2-aminophenyl)benzamide	C₁₅H₁₅N₃O₂
tolevamerum	tolevamer	poly[1-(4-sulfophenyl)ethylene]	(C₈H₈O₃S)ₙ
etiprednol dicloacetate	dicloacétate d'etiprednol	17-[(dichloroacetyl)oxy]-11β-hydroxy-3-oxoandrosta-1,4-diene-17β-carboxylate d'éthyle	C₂₄H₃₀Cl₂O₆
axomadol	axomadol	(2S)-2-(4-aminophenyl)propan-2-ol	C₁₆H₂₅NO₃

Additional Notes

The Procedure and Guiding Principles for selecting INN names are detailed and will only appear in the odd-numbered proposed INN lists.
The INN system is used to ensure that pharmaceutical substances are named consistently across countries and languages.
The names in the lists are intended for identification purposes only and do not imply any recommendation for medical use.
The Cumulative List No. 10, 2002 is the source of the names and is available only in CD-ROM format.

This document serves as a reference for the standardized naming of pharmaceutical substances and is an important tool for international pharmaceutical communication.

展开完整摘要